Ultrasound as a treatment modality for neurological diseases

Gerhard Leinenga, Rebecca M Nisbet and Jürgen Götz
Med J Aust 2017; 206 (11): . || doi: 10.5694/mja16.01013
Published online: 19 June 2017

Neurological disorders are a particular challenge for therapeutic intervention — ultrasound has emerged as a novel approach with a broad range of applications

With an ageing population, neurological disorders present an increasing challenge to our health care systems. Although antibodies are increasingly being explored for therapeutic intervention,1 the inefficiency of their uptake by the brain means that the estimated cost of a vaccine to treat neurodegenerative disorders such as Alzheimer disease (AD) will exceed US$25 000 per patient per year.2 Not only is this expected to challenge the health care systems of many countries, it also raises ethical issues associated with making these vaccines available to every patient.

  • Queensland Brain Institute, University of Queensland, Brisbane, QLD


Competing interests:

No relevant disclosures.

  • 1. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 2015; 85: 1162-1176.
  • 2. Golde TE. Open questions for Alzheimer’s disease immunotherapy. Alzheimers Res Ther 2014; 6: 3.
  • 3. Sumbria RK, Hui EK, Lu JZ, et al. Disaggregation of amyloid plaque in brain of Alzheimer’s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm 2013; 10: 3507-3513.
  • 4. Nisbet RM, Polanco JC, Ittner LM, Götz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol 2014; 129: 207-220.
  • 5. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32: 1959-1972.
  • 6. Leinenga G, Langton C, Nisbet R, Götz J. Ultrasound treatment of neurological diseases - current and emerging applications. Nat Rev Neurol 2016; 12: 161-174.
  • 7. Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016; 375: 730-739.
  • 8. Leinenga G, Götz J. Scanning ultrasound removes amyloid-beta and restores memory in an Alzheimer’s disease mouse model. Sci Transl Med 2015; 7: 278ra233.
  • 9. Wrenn SP, Dicker SM, Small EF, et al. Bursting bubbles and bilayers. Theranostics 2012; 2: 1140-1159.
  • 10. Coluccia D, Fandino J, Schwyzer L, et al. First noninvasive thermal ablation of a brain tumor with MR-guided focused ultrasound. J Ther Ultrasound 2014; 2: 17.
  • 11. Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med 2016; 8: 343re342.
  • 12. Götz J, Ittner LM. Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9: 532-544.
  • 13. Schneider LS, Mangialasche F, Andreasen N, et al. Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014. J Intern Med 2014; 275: 251-283.
  • 14. Nisbet RM, van der Jeugd A, Leinenga G, et al. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain 2017; doi: 10.1093/brain/awx052 [Epub ahead of print].
  • 15. Hatch RJ, Leinenga G, Götz J. Scanning ultrasound (SUS) causes no changes to neuronal excitability and prevents age-related reductions in hippocampal CA1 dendritic structure in wild-type mice. PLoS One 2016; 11: e0164278.
  • 16. Jordao JF, Thevenot E, Markham-Coultes K, et al. Amyloid-beta plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp Neurol 2013; 248: 16-29.
  • 17. Downs ME, Buch A, Sierra C, et al. Long-term safety of repeated blood-brain barrier opening via focused ultrasound with microbubbles in non-human primates performing a cognitive task. PLoS One 2015; 10: e0125911.
  • 18. Liu HL, Hsu PH, Lin CY, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology 2016; 281: 99-108.
  • 19. Deloitte Access Economics. Dementia across Australia: 2011-2050. Canberra: Deloitte Access Economics, 2011. (accessed Apr 2017).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.